Le Lézard
Classified in: Health
Subjects: CALENDAR OF EVENTS, HEALTH, Clinical Study

The Insulin-Only Bionic Pancreas Pivotal Trial Showed Consistent Mean HbA1c Reductions Across a Variety of Subgroups at ADA's 82nd Scientific Sessions

Caution: The iLet® Bionic Pancreas is an investigational device limited by Federal (or United States) law to investigational use. Not available for sale.

CONCORD, Mass., June 09, 2022 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. ? The results of the multi-center randomized Insulin-Only Bionic Pancreas Pivotal Trial (IO BPPT) were presented during a session hosted by Dr. Roy W. Beck and clinical investigators at the American Diabetes Association (ADA) 82nd Scientific Sessions. The trial met key endpoints, including consistently showing reduced mean HbA1c across populations regardless of race, education, or income level in exploratory analyses of subpopulations. Dr. Gregory Forlenza explained the study design, remarking that the iLet Bionic Pancreas helped to "remove numeracy" from the management of type 1 diabetes.

The randomized trial included a more diverse population of participants with T1D than pivotal studies of other AID systems with respect to minority representation, method of insulin delivery, and HbA1c levels. The results from pre-specified subgroup analyses of the iLet in adults, youth, and the iLet with Fiasp® in adults from the IO BPPT as presented at ADA are summarized below.

"We know that health inequities exist in almost every aspect of healthcare delivery: Type 1 diabetes is no exception," said Martha Goldberg Aronson, Interim CEO and Board Director, Beta Bionics. "Beta Bionics is thrilled to see that exploratory analyses consistently indicate glycemic improvements across race, education, and income from the IO BPPT. This supports our public benefit commitment to making type 1 diabetes management technology accessible to the many."

The session provided details on the iLet in adults, youth, and the iLet with Fiasp in adults in the IO BPPT. The following investigators participated in the session moderated by Dr. Roy Beck:

"As a nurse practitioner and diabetes care and education specialist, I have always said a diagnosis of diabetes does not come with a math degree," said Jeanne Jacoby, FNP, CDCES, Director of Medical Affairs, Beta Bionics, and a person living with diabetes. "I was excited to see that the exploratory sub-group analysis shows consistently reduced mean HbA1c regardless of education level for those in the bionic pancreas group."

Insulin-Only Bionic Pancreas Pivotal Trial (IO BPPT) Results & Background
The pivotal trial was designed to test the safety and efficacy of the iLet Bionic Pancreas relative to a standard of care control group over a 13-week study period. The standard of care group was comprised approximately one-third each on automated insulin delivery (AID) systems, insulin-pump therapy with continuous glucose monitoring (CGM), and multiple daily injection therapy with CGM. The trial was conducted in a home-use setting and enrolled 440 adults and children aged 6 years and older with type 1 diabetes. The primary analysis of the trial compared the iLet, using Humalog® or NovoLog®, versus standard of care in 326 adults and children; the remaining 114 adult participants used the iLet with Fiasp®.

The trial was designed to reach a broad demographic with respect to race, ethnicity, age, therapy type, and baseline glycemic control. The IO BPPT population was more diverse and representative of people with type 1 diabetes in the United States than any previous pivotal trial of an AID system. The racial and ethnic composition in the primary analysis included 74% White non-Hispanic, 10% Black non-Hispanic, 10% Hispanic or Latino, and 6% other or more than one race.

The IO BPPT was a multi-center, randomized controlled trial funded, in part, by a grant from the National Institutes of Health to Boston University, and conducted in collaboration with the IDE sponsor and study coordinator, the Jaeb Center for Health Research, and 16 clinical research centers across the U.S.

For more information on the IO BPPT results, read the previous data release: The iLet® Bionic Pancreas Significantly Reduced HbA1c and Improved Time in Range vs Standard of Care for a Diverse Range of People with Type 1 Diabetes.

About the iLet® Bionic Pancreas
The iLet® is a pocket-sized, wearable investigational medical device designed to autonomously dose insulin. It is designed to be worn like an insulin pump; however, iLet® users would enter only their body weight to initialize therapy and would not set any insulin regimen parameters. The iLet® is designed to then automatically titrate and infuse insulin without requiring the user to count carbohydrates, set insulin-to-carbohydrate ratios, set insulin basal rates, set correction factors, or determine bolus insulin for meals or corrections. The technology is designed to help a broad base of people who wish to use technology to manage diabetes.

About Beta Bionics
Beta Bionics® is a clinical stage medical technology company focused on the design, development, and commercialization of its iLet® Bionic Pancreas in both the insulin dosing (the iLet®) and bihormonal (iLet Duotm) configurations. The iLet® Bionic Pancreas platform is designed to use adaptive, self-learning, control algorithms, together with continuous glucose monitoring and pump technology, to autonomously compute and administer doses of insulin and/or glucagon and mimic the body's natural ability to maintain tight glycemic control.

Beta Bionics is a for-profit, public benefit corporation and Certified B Corporationtm. Since its founding in 2015, its mission is to help improve health outcomes and the quality of life of children and adults living with diabetes and other conditions of glycemic dysregulation.

Beta Bionics operates in Massachusetts and California. For further information, visit www.betabionics.com or follow Beta Bionics on Facebook, YouTube, Instagram, LinkedIn, and Twitter @BetaBionics.

Caution: The iLet® Bionic Pancreas is an investigational device limited by Federal (or United States) law to investigational use. Not available for sale.

1. Beck, R., Forlenza, G., Kruger, D., Messer, L.,& Russell, S. (2022, June 3). The Insulin-Only Bionic Pancreas Pivotal Trial?Randomized Clinical Trial Results [Mini Symposium]. ADA's 82nd Scientific Sessions, New Orleans, LA, United States.

Investor Relations Contact:
Hattie Bailey
Senior Investor Relations Manager & Assistant Corporate Secretary
[email protected]

Media and Public Relations Contact:
Katy O'Neill
Beehive Strategic Communication
[email protected]

These press releases may also interest you

at 10:30
HeartVista, a pioneer and leader in automated MRI solutions, today announced that it has changed its name to Vista.ai as the company broadens its sights to simplify and enhance MRI exams for anatomies beyond the heart. A major academic medical center...

at 10:25
Edwards Lifesciences Corporation announced that one-year results on patients treated in the single-arm, prospective, global, multi-center TRISCEND study of the company's EVOQUE transcatheter tricuspid valve replacement system demonstrated favorable...

at 10:00
Aidoc, the leading provider of healthcare AI solutions, enters the Radiological Society of North America's (RSNA) 2022 annual meeting with a series of recent clearances, accolades and investments demonstrating the continued rapid adoption?and massive...

at 10:00
Seno Medical, makers of the Imagio® Breast Imaging System - a revolutionary new modality in breast imaging - will officially launch the commercially available system at the annual RSNA Scientific Assembly and Annual Meeting starting November 27...

at 09:30
Annalise.ai, which was just named 2022's "Best New Radiology Vendor" by AuntMinnie.com, is celebrating yet another stellar year of growth and innovation at the Radiological Society of North America (RSNA) 2022 Annual Meeting. "Our appearance at RSNA...

at 09:00
November 27, 2022 Latest innovations feature vendor-neutral solutions to help reduce clinical complexity and enhance operational efficiency to address workforce shortages and staff burnout and enable a clear care pathway for every patient...

News published on 9 june 2022 at 14:00 and distributed by: